etherna Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
89
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$34.1M
etherna General Information
Description
Developer of precision therapeutics intended to develop next-generation targeted therapies through proprietary single-domain antibody and drug conjugate platforms. The company specializes in developing next-generation products with antibody engineering, target identification, drug conjugate development, preclinical research, and R&D collaborations, enabling biopharmaceutical partners to develop targeted therapeutic candidates and advance drug development programs.
Contact Information
Website
www.etherna.be(Operating Subsidiary)
Corporate Office
- Galileilaan 19
- 2845 Niel
- Belgium
Corporate Office
- Galileilaan 19
- 2845 Niel
- Belgium
etherna Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 12-Oct-2026 | $34.1M | Completed | Generating Revenue | ||
| 7. Later Stage VC (Series B2) | 23-Aug-2022 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series B) | 16-Jun-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 25-Jul-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 05-Jul-2018 | Completed | Generating Revenue | |||
| 3. Grant | 25-Sep-2017 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 05-Jan-2017 | Completed | Generating Revenue | |||
| 1. University Spin-Out | 01-Jan-2013 | Completed | Startup |
etherna Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference B2 | ||||||||
| Preference B2 | ||||||||
| Preference B2 | ||||||||
| Class B | ||||||||
| Class B | ||||||||
| Class B | ||||||||
| Class B | ||||||||
| Preference A | ||||||||
| Preference | 4,592 | $2.45 | $2.45 | 1x | $2.45 | 0.31% | ||
| Preference | 22,733 | $1.43 | $1.43 | 1x | $1.43 | 1.54% |
etherna Comparisons
Industry
Financing
Details
etherna Competitors (32)
One of etherna’s 32 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| TME Pharma | Formerly VC-backed | Berlin, Germany | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| Transgene | Corporation | Illkirch-Graffenstaden, France | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
etherna Patents
etherna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026171886-A1 | Mrna combination for use in preventing and/or treating an autoimmune disease | Pending | 13-Feb-2025 | ||
| WO-2026093528-A1 | A purification of rna by flowthrough chromatography | Pending | 31-Oct-2024 | ||
| WO-2026047192-A1 | Ionizable lipids | Pending | 30-Aug-2024 | ||
| WO-2026008584-A1 | Stabilizing lipids | Pending | 01-Jul-2024 | ||
| AU-2024403484-A1 | Lipid nanoparticles | Pending | 22-Dec-2023 | A61K9/0019 |
etherna Signals
etherna Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BNP Paribas Fortis Private Equity | Growth/Expansion | Minority | ||
| Boehringer Ingelheim Venture Fund | Corporate Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Fund+ | Venture Capital | Minority | ||
| Grand Decade | Corporation | Minority |
etherna Investments (2)
etherna’s most recent deal was a Early Stage VC with Traianus Partners. The deal was made on 28-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Traianus Partners | 28-Mar-2024 | Early Stage VC | Other Financial Services | ||
| AuroRNA Biotech | 25-Nov-2020 | Joint Venture | Biotechnology |
etherna FAQs
-
When was etherna founded?
etherna was founded in 2013.
-
Where is etherna headquartered?
etherna is headquartered in Niel, Belgium.
-
What is the size of etherna?
etherna has 89 total employees.
-
What industry is etherna in?
etherna’s primary industry is Biotechnology.
-
Is etherna a private or public company?
etherna is a Private company.
-
What is the current valuation of etherna?
The current valuation of etherna is .
-
What is etherna’s current revenue?
The current revenue for etherna is .
-
How much funding has etherna raised over time?
etherna has raised $122M.
-
Who are etherna’s investors?
BNP Paribas Fortis Private Equity, Boehringer Ingelheim Venture Fund, EQT Life Sciences, Fund+, and Grand Decade are 5 of 14 investors who have invested in etherna.
-
Who are etherna’s competitors?
Adaptimmune Therapeutics, TME Pharma, WaVe Life Sciences, Transgene, and Immunocore Holdings are some of the 32 competitors of etherna.
-
When was etherna acquired?
etherna was acquired on 12-Oct-2026.
-
Who acquired etherna?
etherna was acquired by Valerio Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process